Fatty diacid is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
== External links == Protamine+Sulfate at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "Protamine Sulfate". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on August 29, 2021.
Trump called on House and Senate Republicans to kill the bill, arguing it would hurt his and the Republican Party's reelection campaigns and deny them the ability to run on immigration as a campaign issue. Harris criticized Trump for his opposition to the bill on the campaign trail, and promised to sign the bill into law as president.
The PLA is governed by the Central Military Commission (CMC); under the arrangement of "one institution with two names", there exists a state CMC and a Party CMC, although both commissions have identical personnel, organization and function, and effectively work as a single body. The only difference in membership between the two occurs for a few months every five years, during the period between a Party National Congress, when Party CMC membership changes, and the next ensuing National People's Congress, when the state CMC changes. The CMC is composed of a chairman, vice chairpersons and regular members. The chairman of the CMC is the commander-in-chief of the PLA, with the post generally held by the paramount leader of China; since 1989, the post has generally been held together with the CCP general secretary. Per the chairman responsibility system, the CMC chairman exercises absolute control over the CMC and the overall military. Unlike in other countries, the Ministry of National Defense and its Minister do not have command authority, largely acting as diplomatic liaisons of the CMC, insulating the PLA from external influence. However, except for the current incumbent, Admiral Dong Jun, the Minister has always been a member of the CMC.
Mg(s) + 2 H2O(l) → Mg(OH)2(aq) + H2(g) However, this reaction is much less dramatic than the reactions of the alkali metals with water, because the magnesium hydroxide builds up on the surface of the magnesium metal and inhibits further reaction. In addition, when reacting with steam it produces magnesium oxide and hydrogen: Mg(s) + H2O(g) → MgO(aq) + H2(g)
Advantage Business Marketing (ABM) was a private American digital marketing and information services company owned by the venture capital firm Owner Resource Group. The company was founded in 2006 and was based in Rockaway, New Jersey, United States. It filed for bankruptcy in June 2019.
Sources: en.wikipedia.org
Jake Carlisle (born 1 October 1991) is a former professional Australian rules footballer who played 66 games for the St Kilda Football Club in the Australian Football League (AFL) until his retirement at the end of the 2021 season. He previously played 85 games for the Essendon Football Club from 2010 to 2015.
== Medical uses == Oxymetazoline is available over-the-counter as a topical decongestant in the form of oxymetazoline hydrochloride in nasal sprays. Due to its vasoconstricting properties, oxymetazoline is also used to treat nosebleeds and eye redness due to minor irritation (marketed as Visine L.R. in the form of eye drops). In the United States, oxymetazoline 1% cream was approved by the Food and Drug Administration (FDA) in January 2017 for topical treatment of persistent facial erythema (redness) associated with rosacea in adults. In July 2020, oxymetazoline received approval by the FDA for the treatment of acquired blepharoptosis (drooping eyelid).
In 1999, the Institute of Medicine published the Safety of Silicone Breast Implants (1999) study that reported no evidence that saline-filled and silicone-gel filled breast implant devices caused systemic health problems; that their use posed no new health or safety risks; and that local complications are "the primary safety issue with silicone breast implants", in distinguishing among routine and local medical complications and systemic health concerns." In 2000, the FDA approved saline breast implant Premarket Approval Applications (PMA) containing the type and rate data of the local medical complications experienced by the breast surgery patients. "Despite complications experienced by some women, the majority of those women still in the Inamed Corporation and Mentor Corporation studies, after three years, reported being satisfied with their implants." The premarket approvals were granted for breast augmentation, for women at least 18 years old, and for women requiring breast reconstruction. In 2006, for the Inamed Corporation and for the Mentor Corporation, the U.S. Food and Drug Administration lifted its restrictions against using silicone-gel breast implants for breast reconstruction and for augmentation mammoplasty. Yet, the approval was conditional upon accepting FDA monitoring, the completion of 10-year-mark studies of the women who already had the breast implants, and the completion of a second, 10-year-mark study of the safety of the breast implants in 40,000 other women.
Barère voiced the Committee of Public Safety's support for the measures desired by the assembly: he presented a decree that was passed immediately, establishing a paid armed force of 6,000 men and 1,000 gunners "designed to crush the counter-revolutionaries, to execute wherever the need arises the revolutionary laws and the measures of public safety that are decreed by the National Convention, and to protect provisions (A force of citizen-soldiers which could go into the countryside to supervise the requisition of grain, to prevent the manoeuvres of rich égoistes and deliver them up to the vengeance of the laws)".) For that reason, twelve travelling tribunals (with moveable guillotines) were set up. Three months later, on 4 December, the departmental revolutionary armies (except in Paris) were banned on proposal of Tallien. The sections lost all rights to control their delegates and officials. On 4 March 1794, there were rumours of uprising in the Cordeliers club. The Hébertists hoped that the National Convention would expel Robespierre and his Montagnard supporters. The sans-culottes did not respond, and Hanriot refused to cooperate. On 13 March Hébert, the voice of the sans-culottes, had been using the latest issue of Le Père Duchesne to criticise Robespierre. On 18 March Bourdon attacked the Commune and the sans-culottes army. Jacques Hébert, Ronsin, Vincent, Momoro, Clootz, De Kock were arrested on charges of complicity with foreign powers (William Pitt the Younger) and guillotined on 24 March.
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.